Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study
Year: 2017
Type: conference-abstract
Source: Blood
Institutions: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Karolinska University Hospital, Karolinska Institutet, Instituto de Investigación Biomédica de Salamanca, Amsterdam UMC Location Vrije Universiteit Amsterdam, Emory University, Winship Cancer Institute, Centre Hospitalier Universitaire de Nantes, Nantes Université, Institut Català d'Oncologia, University of Southern Denmark, Vejle Sygehus, Centre Hospitalier Universitaire de Tours, Janssen (Belgium), Janssen Research & Development (United States), Clinica Universidad de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Centro de Investigación Médica Aplicada, Carolinas Healthcare System, Levine Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2784140703